Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
for Beta-Thalassemia
3 locations incl. New York
Sponsor: Vertex Pharmaceuticals Incorporated
Sex: All·Age: 12 - 35
Code: NCT05477563·Phase 3·Recruiting·Listed Jul 2022